Globalepolicy.org is a free to access global medical news service for the consumer, professional and researcher.
Our adviser: Drugs Infromation online
Background: A treatment algorithm and screening examination have been developed to guide patient management and prospectively determine potential for highly active individuals to succeed with nonoperative care after anterior cruciate ligament rupture.
Objective: To prospectively characterize and classify the entire population of highly active individuals over a 10-year period and provide final outcomes for individuals who elected nonoperative care.
Methods: Inclusion criteria included presentation within 7 months of the index injury and an International Knee Documentation Committee level I or II activity level before injury. Concomitant injury, unresolved impairments, and a screening examination were used as criteria to guide management and classify individuals as noncopers (poor potential) or potential copers (good potential) for nonoperative care.
Results: A total of 832 highly active patients with subacute anterior cruciate ligament tears were seen over the 10-year period; 315 had concomitant injuries, 87 had unresolved impairments, and 85 did not participate in the classification algorithm. The remaining 345 patients (216 men, 129 women) participated in the screening examination a mean of 6 weeks after the index injury. There were 199 subjects classified as noncopers and 146 as potential copers. Sixty-three of 88 potential copers successfully returned to preinjury activities without surgery, with 25 of these patients not undergoing anterior cruciate ligament reconstruction at the time of follow-up.
Conclusion: The classification algorithm is an effective tool for prospectively identifying individuals early after anterior cruciate ligament injury who want to pursue nonoperative care or must delay surgical intervention and have good potential to do so.
NAVIGATION
|
28
Oct |
Abbott’s Genetic Test For Acute Myeloid Leukemia Prognosis Cleared By FDACategory: Lymphoma / Leukemia / Myeloma | Leave a Comment |
Abbott (NYSE: ABT) announced it has received 510(k) clearance from the U.S. Food and Drug Administration for a new in vitro diagnostic test to aid in determining the prognosis of patients with acute myeloid leukemia (AML), one of the most common types of leukemia in older adults…
|
2
Dec |
Signal Genetics Announces Launch Of Revolutionary Molecular Test For Multiple Myeloma PatientsCategory: Lymphoma / Leukemia / Myeloma | Leave a Comment |
Signal Genetics, the parent company of Myeloma Health, a privately held predictive genetic testing company focused on oncology, today announced the launch of their revolutionary molecular test for individuals diagnosed with multiple myeloma, MyPRS™…
|
27
Jun |
Quantum Dot Technique For Cancer Biopsy DiagnosisCategory: Lymphoma / Leukemia / Myeloma | Leave a Comment |
The tunable fluorescent nanoparticles known as quantum dots make ideal tools for distinguishing and identifying rare cancer cells in tissue biopsies, Emory and Georgia Tech scientists have demonstrated…
|
8
Oct |
Leukemia Cell Detection Enhanced By High-Sensitivity Bone Marrow Aspiration TechnologyCategory: Lymphoma / Leukemia / Myeloma | Leave a Comment |
Scientists have created a viable technology to improve the detection of leukemia cells in bone marrow. Superconducting Quantum Interference Device (SQUID) enhanced the ability to rapidly quantify the amount of nanoparticle bound tumor cells in a sample at least 10 fold, and increased sensitivity of minimal residual disease measurements. Results of this proof-of-concept study are published in Cancer Research, a journal of the American Association for Cancer Research.
|
26
Sep |
Funding Boost To Speed Up Cancer Detection For Canadian Research Network Led By University Of Toronto ChemistCategory: Lymphoma / Leukemia / Myeloma | Leave a Comment |
A nanomedicine research group led by a University of Toronto chemist has received a $5-million grant from the Natural Sciences and Engineering Research Council of Canada (NSERC), giving them the green light to develop faster ways of detecting leukemia and lung cancer cells. “This funding will lead to healthier lives for Canadians,” says Gilbert Walker, a professor in U of T’s Department of Chemistry and primary investigator of the Network for Bioplasmonic Systems (BiopSys).